• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

supervision of medical device business
Monday, 25 April 2022 / Published in Medical Device, News, NMPA Registration in China

Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates

Supervision of medical device business operation in China will be strengthened when the new regulatory measures come into effect on May 1, 2022.

On March 22, 2022, the National Medical Products Administration (NMPA) published (No.54-2022) the amended version of the Administrative Measures for the Supervision of Medical Device Business Operation to replace the previous CFDA Order No.8 announced on July 30, 2014.

Supervision of Medical Device Business Operation – Highlights

The key points about which medical device manufacturers should be aware have been summarised by our regulatory experts below.

  • Business license and some other supporting materials will no longer be required in the application of obtaining business operation approval. The dossier submission and on-site inspection can be carried out once if the same applicant applies for class III medical device business operation approval and the filing of class II medical device business operation at the same time. If the class III medical device business operation approval has already been obtained, the submission of the corresponding information for the filing of class II medical device can be exempted.
  • The internal review for business operation approvals will be reduced from 30 working days to 20 working days.
  • The NMPA announced a list of 13 class II medical devices that will be exempted from business operation filing as the effectiveness and safety of the product won’t be affected by the distribution process. Medical device registrants or filers that are selling the products in their own residential address or manufacturing sites, as well as non-profit organizations handling the storage, distribution, and supply of contraceptive medical devices will all be exempted from business operation filing.
  • Public statement declaring the loss of the business operation approval certificate will no longer be required to apply for a new certificate.

On March 22, 2022, the NMPA published (No.53-2022) the amended version of the Administrative Measures for the Supervision of Medical Device Manufacturing to replace the previous CFDA Order No.7 announced on July 30, 2014. Read our separate blog post for more information.

By Julie Zhang and Jacky Li. If you would like to learn more about supervision of medical device business operations in China or our registration and CRO services for medical devices, IVDs, pharmaceuticals, cosmetics or other products, please contact Cisema.

Tagged under: medical device, medical device business operation

What you can read next

China NMPA Finalizes the “Measures for the Supervision and Administration of Production and Operation of Cosmetics”
First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area
China Regulatory Framework for AI

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.